Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$92.56M-4.1%-$88.91M-20.3%-$73.93M-3.9%-$71.13M-2.6%-$69.3M-18.1%
$39K+39.3%$28K+47.4%$19K-58.7%$46K-2.1%$47K0.0%
$17.11M+72.2%$9.94M+33.4%$7.45M-4.2%$7.77M-11.6%$8.79M+2.5%
$6.53M$1.99M-66.5%$5.92M-42.9%$10.38M
-$17.39M-220%$14.43M-$8.28M-202%
-$672K-$280K+95.8%-$6.64M-176%
$0-100%$13K+230%-$10K-900%-$1K+50.0%-$2K-200%
$197K-27.3%$271K+3.0%$263K+2.3%$257K+3.2%$249K+2.5%
-$101K-$303K-7.6%
-$86.15M-12.9%-$76.33M-17.3%-$65.06M-19.0%-$54.68M-3.1%-$53.01M+5.5%
$62K$56K$0
$486.78M+24.7%$390.28M+419%$75.13M+81.7%$41.35M-64.7%$117.06M+68.6%
-$344.28M-4.8%-$328.39M-751%$50.41M$0+100%-$51.06M-368%
$1.12M-90.4%$11.61M+1,337%$808K+175%$294K-47.5%$560K-71.6%
$12.92M+1,478%$819K+1,475%$52K+126%$23K-98.1%$1.2M+661%
$609.43M-0.5%$612.52M+8,966%$6.76M-76.4%$28.63M-47.2%$54.27M-52.3%
$179M-13.9%$207.8M+2,734%-$7.89M+3.2%-$8.15M+83.6%-$49.81M-207%
$655K-2.4%$671K-4.8%$705K-28.6%$987K-19.7%$1.23M-11.6%
$39K+39.3%$28K+47.4%$19K-58.7%$46K-2.1%$47K0.0%
-$101K-$303K-7.6%
-$672K-$280K+95.8%-$6.64M-176%
$197K-27.3%$271K+3.0%$263K+2.3%$257K+3.2%$249K+2.5%
$1.75K0.0%$1.75K0.0%$1.75K0.0%$1.75K
$0$64K
-$101K-$303K-7.6%
$4.09M$0
$1.43M$0
-$86.21M-13.0%-$76.33M-17.3%-$65.06M-18.9%-$54.73M-3.2%-$53.01M+5.5%
-$86.21M-13.0%-$76.33M-17.3%-$65.06M-18.9%-$54.73M-3.2%-$53.01M+5.5%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Praxis Precision Medicines, Inc. generate?
Praxis Precision Medicines, Inc. (PRAX) generated -$282.2M in operating cash flow over the trailing twelve months.
What is Praxis Precision Medicines, Inc.'s free cash flow?
After $118.0K of capital expenditures, Praxis Precision Medicines, Inc.'s free cash flow was -$282.3M over the trailing twelve months, down 72.3% year over year.
Where does Praxis Precision Medicines, Inc.'s cash flow data come from?
Every line is extracted from Praxis Precision Medicines, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.